0B68 Fortina, Paolo M. - Thomas Jefferson University - Thomas Jefferson University

Paolo M. Fortina, MD, PhD

Contact Dr. Fortina

Kimmel Cancer Center
233 S. Tenth Street, Suite 1009
Philadelphia, PA 19107

(215) 955-0683
(215) 503-9142 fax

Most Recent Peer-reviewed Publications

  1. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  2. The future of laboratory medicine - A 2014 perspective
  3. Performance of exome sequencing for pharmacogenomics
  4. Clinical exome performance for reporting secondary genetic findings
  5. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  6. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer
  7. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics
  8. The human platelet: Strong transcriptome correlations among individuals associate weakly with the platelet proteome
  9. Genomic test validation for incidental findings
  10. Clinical genomics: When whole genome sequencing is like a whole-body CT scan
  11. Bridging genomics research between developed and developing countries: The Genomic Medicine Alliance
  12. Genomics into Healthcare: The 5th Pan Arab Human Genetics Conference and 2013 Golden Helix Symposium
  13. Donor splice-site mutation in CUL4B is likely cause of X-linked intellectual disability
  14. Mechanisms of endothelial cell attachment, proliferation, and differentiation on 4 types of platinum-based endovascular coils
  15. Functional significance of macrophage-derived exosomes in inflammation and pain
  16. Developmental dysplasia of the hip: Linkage mapping and whole exome sequencing identify a shared variant in CX3CR1 in all affected members of a large multigeneration family
  17. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors
  18. Cyclin D1 induction of dicer governs microRNA processing and expression in breast cancer
  19. Next-generation sequencing in the clinic
  20. Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab